Floatz logo

trx103

Acute Lymphoblastic Leukemia, Adult B-Cell

Tr1X, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Acute Lymphoblastic Leukemia, Adult B-Cell cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
Mayo Clinic
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

trx103 is also rated in:

Crohn diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
CC
Indicative ·
43 / 100
View asset →
graft versus host diseaseDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →